Algeta ASA

Oslo, Norway

Algeta ASA

Oslo, Norway

Time filter

Source Type

Patent
Algeta ASA | Date: 2014-05-21

The present invention relates to a method for the generation of ^(223)Ra of pharmaceutically tolerable purity comprising:i) preparing a generator mixture comprising ^(227)Ac, ^(227)Th and ^(223)Ra in a first aqueous solution comprising a first mineral acid;ii) loading said generator mixture onto a DGA separation medium (e.g. resin);iii) eluting said ^(223)Ra from said DGA separation medium using a second mineral acid in a second aqueous solution to give an eluted ^(223)Ra solution; andiv) stripping the DGA separation medium of said ^(227)Ac and ^(227)Th by flowing a third mineral acid in a third aqueous solution through the DGA separation medium in a reversed direction; The invention further relates to high purity radium-223 formed or formable by such a method as well as pharmaceutical compositions comprising such radium-223 of pharmaceutical purity.


Patent
Algeta ASA | Date: 2013-05-13

A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.


Patent
Algeta ASA | Date: 2015-04-01

The present invention provides ^(223)Ra comprising no more than 0.05 Bq ^(227)Ac per 1MBq ^(223)Ra. The ^(223)Ra may be formed or formable by a method comprising:i) preparing a generator mixture comprising ^(227)Ac, ^(227)Th and ^(223)Ra;ii) loading said generator mixture onto a strong base anion exchange resin;iii) eluting said ^(223)Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted ^(223)Ra solution;iv) loading the ^(223)Ra of the first eluted ^(223)Ra solution onto a strong acid cation exchange resin; andv) eluting the ^(223)Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution.


Patent
Algeta ASA | Date: 2014-12-16

The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed.


Patent
Algeta ASA | Date: 2012-03-29

A pharmaceutical preparation comprising at least one complexed alpha-emitting radionuclide and at least one polysaccharide biopolymer.


Patent
Algeta ASA | Date: 2013-05-13

A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.


Patent
Algeta ASA | Date: 2014-11-20

The present invention provides a method for the generation of ^(223)Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising ^(227)Ac, ^(227)Th and ^(223)Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said ^(223)Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted ^(223)Ra solution; iv) loading the ^(223)Ra of the first eluted ^(223)Ra solution onto a strong acid cation exchange resin; and v) eluting the ^(223)Ra from said strong acid cation exchange resin losing a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.


Patent
Algeta ASA | Date: 2014-02-19

The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.


Patent
Algeta ASA | Date: 2012-07-12

The present invention relates to a container for liquids, a method of filling it and the use of the container according to the invention for holding and storing radioactive substances. The container for a liquid comprises a cavity for holding the liquid, the cavity being bounded by walls (1) at the sides and at the bottom, an opening for filling the cavity with the liquid, a closure for closing off the cavity, the closure having a piercing region for inserting a cannula into the cavity, a bottom casing (20) which surrounds the walls of the cavity in the standing area, a top casing (10) which surrounds the pierceable closure with the exception of the piercing region, and a film (30) which extends from the top casing to the bottom casing and surrounds those areas of the walls of the cavity which are not already surrounded by the top casing or bottom casing.


Patent
Algeta ASA | Date: 2013-05-13

A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyi solubilising group and wherein the tissue targeting moiety has binding affinity for the CD33 receptor. A corresponding pharmaceutical formulation and method and use in treatment, as well as methods of manufacture are provided.

Loading Algeta ASA collaborators
Loading Algeta ASA collaborators